Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q4
Sell
-8,200
Closed -$359K 1265
2022
Q3
$359K Sell
8,200
-85,600
-91% -$4.16M 0.01% 874
2022
Q2
$4.92M Buy
93,800
+50,900
+119% +$2.59M 0.18% 142
2022
Q1
$2.22M Sell
42,900
-71,300
-62% -$3.7M 0.08% 297
2021
Q4
$6.74M Sell
114,200
-34,600
-23% -$1.71M 0.23% 73
2021
Q3
$6.4M Buy
148,800
+66,300
+80% +$2.94M 0.21% 77
2021
Q2
$3.23M Buy
82,500
+49,100
+147% +$1.91M 0.1% 243
2021
Q1
$1.21M Sell
33,400
-27,000
-45% -$959K 0.04% 579
2020
Q4
$2.22M Buy
+60,400
New +$2.22M 0.1% 250

Other funds holding PFE

Point72 Hong Kong's PFE Position: Q2 2024 in Review

Point72 Hong Kong sold out of Pfizer (PFE) in Q2 2024, closing a stake of 1,859 shares — an estimated $51.6K sold.

Point72 Hong Kong first reported a position in PFE in Q1 2015 and held it in 19 quarters. The position peaked at $4.75M in Q1 2020. 2,874 funds tracked by Wall St. Rank hold PFE as of Q2 2024.

  • Point72 Hong Kong reported no remaining Pfizer position as of Q2 2024 after selling out during the quarter.
  • Point72 Hong Kong sold 1,859 Pfizer shares in Q2 2024, an estimated $51.6K.
  • Point72 Hong Kong first reported a position in Pfizer in Q1 2015 and held it in 19 quarters.
  • Point72 Hong Kong's Pfizer position peaked at $4.75M in Q1 2020.
  • 2,874 funds tracked by Wall St. Rank held Pfizer as of Q2 2024.

Based on Point72 Hong Kong's 13F filing for Q2 2024, filed 14 Aug 2024.